Results 91 to 100 of about 7,551 (201)

Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels [PDF]

, 2008
Background/aim: To examine the risks for hepatocellular carcinoma (HCC) with respect to hepatitis B virus (HBV) genotypes, specific viral mutations (MT), serum HBV DNA levels, and cirrhosis. Methods: HBV genotypes, 1653/1753/core promoter (CP)/precore MT
But, DYK, Fong, DYT, Fung, J, Lai, CL, Mizokami, M, Poon, RT, Shinkai, N, Tanaka, Y, Wong, DKH, Yuen, JCH, Yuen, MF   +10 more
core   +1 more source

Hepatitis B Reactivation in Biologic‐Treated Moderate‐to‐Severe Psoriasis: A Real‐World Cohort Study With 534 Patient‐Years of Follow‐Up

Dermatologic Therapy, Volume 2026, Issue 1, 2026.
Background Psoriasis vulgaris is a chronic immune‐mediated inflammatory disease frequently requiring long‐term biologic therapy. Although biologics targeting TNF‐α and interleukin pathways have revolutionized disease management, they may disrupt antiviral immune surveillance and trigger hepatitis B virus (HBV) reactivation in individuals with prior HBV
Neslihan Demirel Öğüt, Muhammed Numan Sarıtaş, Merve Duğan, Ece Erbağcı, Sema Koç Yıldırım, Simge Ünal Işık, Ece Gökyayla, Suraiya Saleem   +7 more
wiley   +1 more source

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis

Virology Journal, 2011
Background Although entacavir and adefovir were widely used in most Asian countries, there were few conclusions drawn from a meta-analysis for comparing the efficacy between entecavir and adefovir in nucleos(t)ide-naïve Asian patients with chronic ...
Zhao Jun, Liu Weiwei, Zhao Pan, Guan Qun
doaj   +1 more source

Clinical trial of lamivudine in children with chronic hepatitis B. [PDF]

, 2002
N Engl J Med. 2002 May 30;346(22):1706-13. Clinical trial of lamivudine in children with chronic hepatitis B. Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM; International Pediatric ...
Areias, J.A., Badia, I.B., Bell, M.S., Gardner, S.D., Greensmith, M.J., International Pediatric Lamivudine Investigator Group., Jonas, M.M., Little, N.R., Mizerski, J., Schwarz, K.B., Sokal, E.M.   +10 more
core   +1 more source

Exploring the Role of CXCL13 in the Immune Response to Hepatitis B Infection: A Systematic Review

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
Background C–X–C motif chemokine ligand 13 (CXCL13) is a critical chemokine for lymphoid organization and immune cell migration during hepatitis B virus (HBV) infection. This systematic review assessed the function of CXCL13 in HBV immunoregulation, pathogenesis, genetic susceptibility, and treatment outcome.
Nura Bello, Shuaibu Abdullahi Hudu, Albashir Tahir, Nura Abubakar, Sa’adatu Haruna Shinkafi, Adamu Ahmed Adamu, Mustapha Umar Imam, Abdulgafar Olayiwola Jimoh, Arif Jamal Siddiqui   +8 more
wiley   +1 more source

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

Infection and Drug Resistance, 2018
 Shaohang Cai,* Zhandong Li,* Tao Yu, Muye Xia, Jie Peng Department of Infectious Diseases and Hepatology Unit, NanFang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China *These authors contributed equally to this ...
Cai S, Li Z, Yu T, Xia M, Peng J
doaj  

Effects of entecavir on hepatitis B virus covalently closed circular DNA in hepatitis B e antigen-positive patients with hepatitis B.

PLoS ONE, 2015
The aim of this study was to assess the effect of 48-week entecavir therapy on serum and intrahepatic hepatitis B virus, covalently closed circular DNA (HBV cccDNA) levels in hepatitis B e antigen (HBeAg)-positive patients.
Ming Shi, Wan-Li Sun, Yan-Yan Hua, Bo Han, Long Shi   +4 more
doaj   +1 more source

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B [PDF]

, 2004
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated ...
Bonino, F, Button, P, Diago, M, Farci, P, Germanidis, G, Gurel, S, Hadziyannis, S, Jin, R, Lai, MY, Lau, GK, Lu, ZM, Marcellin, P, Piratvisuth, T, Pluck, N, Yurdaydin, C   +14 more
core   +2 more sources

Hepatitis B Virus Genomic Variability & HBV‐Related Disease Outcomes: A Molecular Epidemiology Perspective

Journal of Medical Virology, Volume 97, Issue 12, December 2025.
ABSTRACT HBV infection remains a major global health challenge, characterized by diverse genotypes with distinct geographical distributions and clinical outcomes. Comprehensive analysis of HBV genomic variability and its association with disease progression is essential for improving clinical management and public health strategies. This study aimed to
Maria Bousali, George Papatheodoridis, Magdalini Bletsa, Dimitrios Paraskevis, Timokratis Karamitros   +4 more
wiley   +1 more source

The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B

The Turkish Journal of Gastroenterology, 2015
Background/Aims: We aimed to investigate the clinical importance of quantitative levels of serum hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), and to detect their correlation with hepatitis B virus (HBV) DNA load, alanine ...
Kaan Demirören, Halil Kocamaz, Yaşar Doğan   +2 more
doaj   +1 more source